Dyadic Revenue Jumps 150% in Fiscal Q2
Dyadic International (NASDAQ:DYAI), a biotechnology company focused on protein and enzyme production through its unique microbial platforms, reported its second quarter 2025 results on August 13, 2025. The highlight was a sharp year-over-year revenue surge, driven primarily by milestone payments and grant revenues. Revenue (GAAP) exceeded consensus estimates by 61.2%. Revenue (GAAP) reached $967,000, beating the $0.60 million analyst estimate (GAAP). Earnings per share (GAAP) came in at a loss of $0.06, matching expectations. Overall, the quarter showed solid operational progress and cost controls, but recurring product revenue remains an area to watch as the company pivots toward greater commercialization.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Dyadic International is a biotechnology firm specializing in producing proteins and enzymes using its C1 and Dapibus microbial expression platforms. The C1 platform focuses on biopharmaceuticals, while Dapibus targets non-pharmaceutical fields such as food, nutrition, and industrial enzymes. These technologies are known for being scalable, cost-efficient, and flexible, offering potential across a wide range of applications.
Source Fool.com
